- Home
- NXPL vs CMMB Comparison
NXPL vs CMMB Comparison
Compare NXPL & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | CMMB |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1M | 19.9M |
| IPO Year | 2011 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NXPL | CMMB |
|---|---|---|
| Price | $9.68 | $2.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 47.5K | ★ 98.7K |
| Earning Date | 05-15-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.29 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $5,869,558.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $68.00 |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $0.34 | $1.35 |
| 52 Week High | $9.87 | $3.55 |
Technical Indicators
Market Signals| Indicator | NXPL | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 78.70 | 81.92 |
| Support Level | $5.54 | $1.47 |
| Resistance Level | N/A | $2.80 |
| Average True Range (ATR) | 0.72 | 0.19 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 94.89 | 77.42 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.